Does Vascepa interact with aspirin?
Vascepa (icosapent ethyl), a purified EPA omega-3 for reducing cardiovascular risk, can increase bleeding risk when combined with aspirin. Both affect platelet function and blood clotting: Vascepa mildly inhibits platelet aggregation, while aspirin strongly does so by blocking thromboxane A2. Clinical data from the REDUCE-IT trial showed higher rates of bleeding events (e.g., epistaxis, hematuria) in patients on Vascepa plus antiplatelets like aspirin, though severe bleeding remained rare (2.7% vs. 2.1% placebo).[1][2]
What bleeding risks do patients report?
Common issues include easy bruising, gum bleeding, or prolonged cuts, especially at higher aspirin doses (81-325 mg daily). In trials, gastrointestinal bleeding occurred in 1-2% more patients on Vascepa + aspirin than aspirin alone. No increased intracranial hemorrhage risk was noted, but caution applies for those with ulcers or recent surgery.[1][3]
Who should avoid or monitor this combination?
High-risk groups: patients on dual antiplatelets (e.g., aspirin + clopidogrel post-stent), those with bleeding disorders, or liver impairment. FDA labeling advises monitoring for bleeding signs and dose adjustments. No absolute contraindication exists, but prescribers often check PT/INR or platelet function tests.[2][4]
How does this compare to fish oil + aspirin?
Vascepa's purified EPA profile causes less bleeding than mixed EPA/DHA fish oils, which amplify aspirin's effects more due to DHA's pro-thrombotic shift. REDUCE-IT confirmed Vascepa's safety edge over generic omega-3s.[1][5]
What do guidelines recommend?
ACC/AHA endorses Vascepa + low-dose aspirin (81 mg) for eligible high-risk patients (e.g., triglycerides 135-499 mg/dL + CVD/MI history), with bleeding risk-benefit weighing. Regular CBC monitoring is standard.[3][6]
Sources
[1]: REDUCE-IT trial (NEJM)
[2]: Vascepa FDA label
[3]: Amarin REDUCE-IT analysis
[4]: Drugs.com interaction checker
[5]: AHA omega-3 review
[6]: 2020 ACC lipid guidelines